Dr. Lanocha is Director of TMS Education at Mindful Health Solutions and has more than 25 years of experience in neuromodulation therapies for treatment-resistant depression, including both TMS and ECT. He was among the first physicians in the country to begin offering TMS when it was approved by the FDA in 2008. He has lectured widely about TMS. His research activities have focused on long-term clinical outcomes following TMS treatment for major depression. Dr. Lanocha co-edited and contributed to “Transcranial Magnetic Stimulation: Clinical Applications for Psychiatric Practice,” which was published by the APA with key research findings on TMS.
Dr. Bermudes is Chief Medical Officer at Mindful Health Solutions. He is the former president and a current board member of the Clinical TMS Society, a professional association dedicated to optimizing clinical practice, awareness, and affordability of Transcranial Magnetic Stimulation therapy. He has consulted with TMS industry leaders to help formulate insurance coverage policies for TMS therapy. He is editor of and contributor to “Transcranial Magnetic Stimulation: Clinical Applications for Psychiatric Practice”.
Dr. Cook founded the UCLA Depression Research & Clinic program in 2007 and the TMS Treatment Service in 2009, becoming the first physician at any University of California campus to treat depression with TMS. In 2008, he was awarded an endowed chair, the Joanne and George Miller & Family Chair in Depression Research, at the UCLA Brain Research Institute. Dr. Cook is an inventor of over three dozen patents on biomedical devices, many of which UCLA has licensed for development. Recently Ian started the Los Angeles TMS Institute where he is focused on TMS innovation and integration. He also serves on the board of CTMS and is a contributor to “Transcranial Magnetic Stimulation: Clinical Applications for Psychiatric Practice."
Previously at Rush University, Dr. Janicak is Consultant to the Therapeutic Neuromodulation Center at Northwestern University. He has long been regarded as a leading expert in psychopharmacology and neuromodulation, including both TMS and ECT. He has written extensively on the long-term safety and efficacy of TMS in treatment resistant-depression, including the pivotal study leading to FDA approval of TMS. Dr. Janicack also co-edited and contributed to “Transcranial Magnetic Stimulation: Clinical Applications for Psychiatric Practice."
Dr. Marton joined the faculty at the UCSF Department of Psychiatry and became a staff Psychiatrist at the San Francisco VA Health Care System. He founded the SFVA ketamine infusion clinic and TMS clinic while remaining active in using ECT to help patients. This ketamine clinic was one of the first in the VA system and had a central role in helping to shape larger initiatives within the VA to make ketamine available to veterans with severe depression and PTSD. He also published several papers examining the ketamine clinic’s patient outcomes and developed training programs for psychiatry residents at UCSF to learn about the use of ketamine and TMS in treating psychiatric illness.